Pancreatic Cancer: Latest Developments

Short summaries of recently published approvals, licensing and reimbursement regulations in Turkey, and notable studies in pancreatic cancer. For general information about the disease, see the Pancreatic Cancer page.

• • FDA Approval
  • Pancreatic Cancer
  • 26 August 2026

  Daraxonrasib receives FDA approval in previously treated metastatic pancreatic cancer

  The FDA approved daraxonrasib, an oral drug targeting RAS proteins, for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or are not suitable for multi-drug chemotherapy. In the RASolute 302 trial, 500 patients whose disease had progressed after one line of treatment were randomised to daraxonrasib or standard chemotherapy chosen by the physician. In the whole patient group, median overall survival was 13.2 versus 6.7 months (hazard ratio 0.40), median progression-free survival 7.2 versus 3.6 months (hazard ratio 0.49); the response rate was 30% versus 11%. Because a KRAS mutation is present in the great majority of pancreatic cancers, this result is considered important. Warnings include skin and oral adverse effects, diarrhoea and pneumonitis.

  Status in Turkey: The TİTCK list of licensed products dated 02.10.2026 contains no product with daraxonrasib.

  • Source:
  • FDA announcement (26 August 2026)
• • FDA Approval
  • Pancreatic Cancer
  • 12 February 2026

  Tumour treating fields (TTFields) device receives FDA approval in locally advanced pancreatic cancer

  The FDA approved a device that applies low-intensity, alternating electric fields through electrodes placed on the skin of the abdomen, used together with gemcitabine and nab-paclitaxel chemotherapy in unresectable locally advanced pancreatic cancer. The approval is based on the phase 3 PANOVA-3 trial. According to results published in the Journal of Clinical Oncology, median overall survival was 16.2 months in the device and chemotherapy arm and 14.2 months in the chemotherapy-only arm (hazard ratio 0.82). Pain-free survival was 15.2 versus 9.1 months; no significant difference was seen in progression-free survival. Device-related skin adverse effects were reported in 76% of patients; most were mild or moderate, and grade 3 skin adverse effects occurred in 7.7%.

  Status in Turkey: The status of use and reimbursement of this device for pancreatic cancer in Turkey has not yet been clarified.

  • Source:
  • FDA press release (12 February 2026)
  • Babiker HM et al. J Clin Oncol 2025;43:2350-2360

There are no developments to show for this selection. You can change the filters and try again.

The news on this page is for general information only; it is not a diagnosis or treatment recommendation. Whether a treatment is suitable for you is decided together with your physician after assessing the characteristics of your disease.